Compare Abeona Therapeutics Inc (ABEO) vs Gartner Inc (IT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gartner Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Gartner Inc trades at $136.16 (market cap $9.43B). The key difference: Gartner Inc is far larger — about 25.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | IT | |
|---|---|---|
Market Cap | $373.32M | $9.43B |
Sector | Health | Technology |
52-Week High | $7.23 | $399.15 |
52-Week Low | $4.17 | $125.68 |
Enterprise Value | $228.22M | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Gartner (IT) trades at $140.80, up 3.29% today, with a bearish technical signal but strong fundamental profitability. Recent earnings consistently beat estimates, with Q1 2026 EPS of $3.32 exceeding the $2.99 forecast. The company maintains robust margins, including a 68.99% gross profit margin and 11.44% net income margin, though 2025 net cash flow was negative $210.63 million. Analyst consensus price target is $158.00, suggesting potential upside from current levels.
The stock offers value with a P/E of 13.35 and P/S of 1.54, but high P/B of 142.72 and negative cash flow trends pose risks. Competitive pressures in IT consulting and reliance on enterprise spending are headwinds. Institutional sentiment is mixed with 27.78% buy ratings, indicating cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
